Results 21 to 30 of about 96,616 (241)

Cladribine for highly active relapsing multiple sclerosis [PDF]

Prescriber, 2018
Cladribine (Mavenclad) is a new oral treatment for adults with highly active relapsing multiple sclerosis. This article summarises its dosing and monitoring requirements, efficacy in the CLARITY trial and place in therapy.
openaire   +1 more source

Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” (October 1, 2023). Main conclusions of the first meeting

Неврология, нейропсихиатрия, психосоматика, 2023
A joint conclusion of the Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” on the organization of medical care, diagnosis and treatment of multiple sclerosis (MS) and other autoimmune diseases is ...
A. N. Boyko, V. V. Vashchilin, O. V. Boyko, A. G. Bunyak, D. S. Kasatkin, D. S. Korobko, S. I. Kulikova, N. V. Mazgo, N. V. Makovskaya, S. A. Sivertseva, I. V. Smagina, T. N. Chernukha   +11 more
doaj   +1 more source

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis [PDF]

Advances in Therapy, 2019
Cost assessment modelling (CAM) of treatments in highly active relapsing multiple sclerosis was conducted.The CAM was developed using the R programming language. The PICOSTEPS health technology assessment framework was applied in the CAM. Modelled patients were 280 adults with highly active relapsing multiple sclerosis eligible for disease-modifying ...
Petri Mankinen, Tuomas Lundström, Erkki Soini, Marja-Liisa Sumelahti, Juhani Ruutiainen, Ulla Niskala, Elina Järvinen   +6 more
openaire   +4 more sources

Impact of autologous HSCT on the quality of life and fatigue in patients with relapsing multiple sclerosis

Scientific Reports, 2022
In this study, we aimed to assess the quality of life, fatigue, anxiety, and depression after Autologous haematopoietic stem cell transplantation (AHSCT) and to investigate its impact of on separate domains of health status and fatigue in patients with ...
N. Giedraitiene, G. Gasciauskaite, G. Kaubrys   +2 more
doaj   +1 more source

Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy

Italian Journal of Pediatrics, 2021
Background Natalizumab is a monoclonal antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis. According to the current clinical recommendations, its use during pregnancy should be carefully evaluated only in women ...
Elisabetta Godano, Fabio Barra, Alessandra Allodi, Antonella Ferraiolo, Alice Laroni, Giovanni Novi, Giovanni Luigi Mancardi, Claudio Gustavino, Cesare Arioni   +8 more
doaj   +1 more source

Aggressive multiple sclerosis in the Republic of Bashkortostan

Неврология, нейропсихиатрия, психосоматика
Treatment of patients with aggressive multiple sclerosis (MS) characterized by severe progression of disability within a short period of time is a complex task as there are no uniform criteria for determining such disease progression type and ...
K. Z. Bakhtiyarova, U. Sh. Kuzmina, O. V. Lyutov, I. D. Talipova, N. F. Akhmetgaleeva, T. R. Galiullin, M. A. Kutlubaev   +6 more
doaj   +1 more source

Cystic echinococcosis causing thrombosis of the inferior vena cava in a patient with multiple sclerosis treated with alemtuzumab

Therapeutic Advances in Neurological Disorders, 2020
Alemtuzumab, one of the very effective immunomodulatory forms of treatment for patients with highly active multiple sclerosis, can also have unexpected side effects.
Ema Kantorová, Veronika Vajdová, Petra Hnilicová, Marek Tarčák, Monika Turčanová, Egon Kurča, Kamil Zeleňák   +6 more
doaj   +1 more source

Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS): “a case report from Ireland with review of literature, clinical pitfalls and future direction”

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021
Background Progressive multifocal leukoencephalopathy (PML) is one of the most serious treatment-related complications that is encountered in patients with multiple sclerosis (MS).
Salman Mansoor, Gerard Mullane, Mohammad Hijaz Adenan, Siobhan Kelly, Aine Water, Grainne McPartland, Kevin Murphy   +6 more
doaj   +1 more source

Systematic literature review and network meta-analysis in highly active relapsing–remitting multiple sclerosis and rapidly evolving severe multiple sclerosis [PDF]

BMJ Open, 2017
Objective Multiple sclerosis (MS) is a chronic, neurodegenerative autoimmune disorder affecting the central nervous system. Relapsing–remitting MS (RRMS) is the most common clinical form of MS and affects ∼85% of cases at onset.
Huisman, Eline, Papadimitropoulou, Katerina, Jarrett, James, Bending, Matthew, Firth, Zoe, Allen, Felicity, Adlard, Nick   +6 more
openaire   +2 more sources

A Bibliometric Analysis of Publications in Uremic Toxins From 1991 to 2024

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Uremic toxins are a growing area of research in nephrology, with significant implications in the progression and treatment of chronic kidney disease (CKD) and the management of end‐stage kidney disease (ESKD). This bibliometric analysis aims to evaluate the global research trends, key contributors, and the impact of publications in ...
Yuh‐Shan Ho, Karim M. Soliman, Wisit Cheungpasitporn, Wannasit Wathanavasin, Ahmed Daoud, Ahmed I. Kamal, Balázs Szamosfalvi, Tibor Fülöp   +7 more
wiley   +1 more source